RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

Gold recently cleared $3,400/oz all-time highs. With significant resources in the ground in Alaska and growing antimony exposure, Nova Minerals Limited (Nasdaq: NVA) is one of the few juniors aligned with both macro momentum and strategic metals demand. Learn more: https://lnkd.in/eVVMfT4u Mines and Money S&P Global Commodity Insights Commodities: Iron, Steel, Copper, Metal, Gold, Silver, Rice, Wheat, Oil, Gas, Coffee, Cotton, Sugar #NovaMinerals #RedChipClient #RedChat #preciousmetals #antimony #Alaska #goldrush #Gold #MiningStocks 

📣 Happening Today: BullFrog AI (Nasdaq: BFRG) Hosts Investor Webinar at 4:15 PM EST BullFrog AI invites investors to a live webinar today at 4:15 PM EST to explore how its proprietary AI platform, bfLEAP®, is reshaping drug discovery for biopharma companies. 💡 Why Tune In: - AI That Delivers: Learn how BullFrog Data Networks® empowers drug developers to identify targets faster, repurpose therapies, and optimize clinical trials—at a fraction of traditional costs. - Market-Driven Strategy: With R&D spending topping $200B annually, $BFRG offers scalable tools to improve success rates and reduce development timelines. - Investor-Focused Growth: Hear directly from leadership about upcoming catalysts, revenue streams, and partnerships with top-tier research institutions. 🔗 https://lnkd.in/eVt344HH Biotechnology Biotechnology News #BullfrogAI #RedChip #RedChat #AI #BiotechStocks #BFRG #DrugDiscovery #Nasdaq #Innovation #Investing

🚀 Nexalin Technology (Nasdaq: NXL) Virtual Clinic Supports TBI/PTSD Military Study Nexalin Technology has completed all five phases of its virtual clinic and digital research ecosystem—now live at UC San Diego to support military-focused TBI/PTSD trials.  💡 Why This Matters for Investors: - Clinical-Grade AI Infrastructure: Enables large-scale remote trials and at-home treatment for both military and civilian populations. - Commercial Readiness: Positions HALO™ for broader adoption with full regulatory compliance and virtual oversight capabilities. - Strategic Milestone: Advances Nexalin Technology's leadership in non-invasive neurostimulation, targeting major markets like mental health, addiction, and neurodegenerative conditions.  🔗 https://lnkd.in/ee8ANUfW Neuroscience News Neurostimulation Biotechnology News #Nexalin #RedChip #RedChat #Biotech #MentalHealth #PTSD #DefenseTech #Investing

🧬 Enlivex Therapeutics (Nasdaq: ENLV) Therapeutics: Showcasing Novel Osteoarthritis Therapy at OARSI 2025 Enlivex will present new data on Allocetra™, its macrophage reprogramming cell therapy, at the prestigious OARSI 2025 World Congress in South Korea. The presentations spotlight encouraging Phase I/II outcomes—highlighting reduced pain, improved joint function, and avoidance of surgery in osteoarthritis (OA) patients. 🧠 Why This Matters to Investors: - Targeting a Major Market: OA affects over 32M Americans, with no current therapies reversing disease progression. - Novel Mechanism: Allocetra™ modulates immune imbalance by reprogramming macrophages—a new frontier in OA treatment. - Strong Early Data: Durable efficacy and favorable safety signal a potential breakthrough in chronic joint inflammation management. 📄 Full Press Release: https://lnkd.in/ewAxjYda Arthritis Biotechnology Biotechnology News #RedChip #RedChat #ENLV #BiotechStocks #Osteoarthritis #ClinicalTrials #HealthcareInnovation #Investing

📢 Calidi Biotherapeutics (NYSE American: CLDI) Prepares for Next Stage of Development with Eric Poma, Ph.D., Taking Helm as CEO Calidi Biotherapeutics has announced the appointment of biotech veteran Eric Poma, Ph.D., as Chief Executive Officer and Director, effective April 22, 2025. Former CEO Allan Camaisa will remain on the Board of Directors. 💡 Why This Matters to Investors: 🔬 Deep Industry Expertise: Dr. Poma brings 30+ years in biopharma, including $250M+ in equity raised and $150M+ in strategic capital through collaborations with Takeda, Vertex Pharmaceuticals, and Bristol Myers Squibb. 🚀 Clinical Momentum: Calidi Biotherapeutics is advancing multiple programs including CLD-201 and RTNova, targeting solid tumors with innovative virotherapy platforms. 📄 Read the Full Announcement:  🔗 https://lnkd.in/eNceVP_3 Oncology Biotechnology Biotechnology News #RedChip #RedChat #CalidiBio #BiotechStocks #Oncology #InvestorUpdate #CancerResearch #FinancialNews

📢 Greenwich LifeSciences (Nasdaq: GLSI): Investor Webinar Set to Spotlight FLAMINGO-01 Phase III Progress Greenwich LifeSciences, Inc. will host a key Investor Webinar next Tuesday at 4:15PM EST, offering an in-depth global update on its Phase III clinical trial, FLAMINGO-01. 💡 Why This Matters to Investors: 🔬 Advancing Toward Commercialization: Early data from both HLA-A02 and non-HLA-A02 patient groups show promising immune response trends, expanding the trial’s potential pathways to approval. 🌍 Global Expansion: With over 117 active sites across the U.S. and EU—and plans to exceed 150—the trial is now one of the most extensive breast cancer studies globally. 🏥 Prestigious Partners: Participation from leading academic hospitals like Stanford University School of Medicine, Harvard Medical School, and Johns Hopkins Medicine, and European networks such as GEICAM, GBG, and Unicancer, adds validation and visibility. 📊 Next Phase of Growth: The webinar will cover clinical updates, regulatory strategy, and commercialization plans, including manufacturing and patent outlooks for GLSI-100. 🔗 https://lnkd.in/efUguQhq Breast Cancer Trials Biotechnology Biotechnology News #RedChip #RedChat #GreenwichLS #BreastCancer #InsiderOwnership #BiotechNews #Oncology #FinancialNews #CapitalMarkets

📢 Institutional Investor Ups Stake in ConnectM (Nasdaq: CNTM) — Now Holds 15.1% Ownership SRISID LLC has disclosed a significant passive investment in ConnectM Technology Solutions, boosting its position to 7.55M shares — representing 15.1% of the company’s outstanding common stock. 💡 Why This Matters to Investors: 🔹 Strategic Signal: SRISID is part of the investor group behind a recent $1.60/share buy-out offer, adding weight to its long-term conviction in ConnectM's value and future potential. 🔹 Investor Confidence: The 13G filing highlights growing institutional interest in ConnectM Technology Solutions's role in the energy transition and smart infrastructure sectors. 🔹 Significant Potential Upside: The buy-out proposal suggests near-term catalysts that could unlock shareholder value. 📄 https://lnkd.in/e_VAfzSc GE Vernova GE Vernova's Electrification businesses S&P Global Commodity Insights #CNTM #AI #Electrification #EV #Investing #EnergyTransition #StockMarket

📢 Investor Alert: BullFrog AI (Nasdaq: BFRG) to Host Live Webinar – April 23, 4:15PM EST Join BullFrog AI’s investor webinar tomorrow to gain key insights into the company’s AI-powered drug discovery platform and strategic roadmap for 2024 and beyond. 💡 Why This Matters to Investors: - AI Advantage in Drug Development: Learn how bfLEAP® and BullFrog Data Networks® uncover hidden insights in complex datasets—transforming R&D for biopharma. - Tapping a $204B Opportunity: BullFrog AI addresses the low 12% success rate in Phase 1 trials with affordable, data-driven solutions. - Dual Revenue Strategy: Combining platform-driven growth with monetization of licensed drug assets and research partnerships. Don’t miss this chance to hear directly from leadership and explore what’s next for this AI-driven biotech innovator. 🔗 https://lnkd.in/eVt344HH AI News Biotechnology News Biotechnology #BullfrogAI #RedChip #RedChat #AI #BiotechStocks #BFRG #DrugDiscovery #Nasdaq #Innovation #Investing

💊 Investors: Aptevo’s (Nasdaq: APVO) December Data Still a Potential Catalyst in 2025 While the data dropped in December, Aptevo Therapeutics Inc's RAINIER results remain a key milestone—100% remission rate in Cohort 1, including a patient with TP53-mutated AML, a notoriously hard-to-treat subtype. 📊 Why It Still Resonates: • MRD-Negative Remissions suggest durability • TP53 Response highlights potential in high-risk AML • Orphan Drug Status remains a valuable regulatory asset 📄 More information available at: https://lnkd.in/ecQN_FCe Biotechnology Biotechnology News #BiotechStocks #AML #ClinicalTrials #CancerResearch #Aptevo #APVO #Oncology